Brendan W. Lunn, M.D.

  1. Nuclear Medicine Specialist
  2. Radiologist
  1. Tapias LF, Shen R, Cassivi SD, Reisenauer JS, Lunn BW, Lechtenberg BJ, Nichols FC, Wigle DA, Blackmon SH. Impact of FDG PET Standardized Uptake Value in Resected Clinical Stage IA Non-Small Cell Lung Cancer. Ann Thorac Surg. 2024 May; 117 (5):1017-1023 Epub 2023 Apr 19
    View PubMed
  2. Bartlett DJ, Takahashi H, Bach CR, Lunn B, Thorpe MP, Broski SM, Packard AT, Fletcher JG, Navin PJ. Potential applications of PET/MRI in non-oncologic conditions within the abdomen and pelvis. Abdom Radiol (NY). 2023 Dec; 48 (12):3624-3633 Epub 2023 May 05
    View PubMed
  3. Lunn B, Yasir S, Lam-Himlin D, Menias CO, Torbenson MS, Venkatesh SK. Anastomosing hemangioma of the liver: a case series. Abdom Radiol (NY). 2019 Aug; 44 (8):2781-2787
    View PubMed
  4. Lunn BW, Littrell LA, Wenger DE, Broski SM. (18)F-FDG PET/CT and MRI features of myxoid liposarcomas and intramuscular myxomas. Skeletal Radiol. 2018 Dec; 47 (12):1641-1650 Epub 2018 June 20
    View PubMed
  5. Bricker-Anthony C, d'Surney L, Lunn B, et al. Erythropoietin either prevents or exacerbates retinal damage from eye trauma depending on treatment timing Optom Vis Sci. 2017; 94(1):20.